Cutting-edge investment ideas in the Biotechnology and Pharmaceutical Industry.  REGISTER NOW to receive $10 worth of FREE credit.  This offer is valid for limited time only.
Cart

ACCURACY OF OPINIONS
80% - Correct
20% - Incorrect
 

RECENT NEWS ON COVERED STOCKS  

ISPH
click here

ACOR
click here

BSTC
click here

DDSS
click here

OPTR
click here

New BioMedicine
Event-based Healthcare Investment Reports
Please point your mouse on the file to get further description of each file.
All Upcoming Events In Biotechnology-February 10, 2010
PDF - Price: $10.00
Add to Cart
30 Upcoming Events-February 10, 2010
PDF - Price: $10.00
Add to Cart

Event Calendars & Data Tables

SAMPLE TABLE – UPCOMING EVENTS (WITHOUT OPINION)
 
EVENT DATE
COMPANY
 
INDICATION
 
 EVENT REPORT DATE REPORT DATE PRICE
January - February 2010 ZymoGenetics, Inc.
(ZGEN)		 First-Line Metastatic Melanoma Phase II trial data of Interleukin-21 (IL-21) November 23, 2009 $5.92
January - February 2010 GTx Inc.
(GTXI)		 Prostate Cancer in Men with High-Grade Prostatic Intraepithelial Neoplasia (PIN) DSMB analysis of the Phase III trial of Acapodene November 26, 2009 $3.87
January - February 2010 Vertex Pharmaceuticals Incorporated
(VRTX)		 Hepatitis C Virus (HCV) Infection SVR data from the Phase III (ADVANCE study) trial of Telaprevir November 30, 2009 $39.00
January - February 2010 OXiGENE, Inc.
(OXGN)		 Anaplastic Thyroid Cancer (ATC) Phase II/III FACT trial data of Zybrestat December 4, 2009 $1.15
January - February 2010 Isis Pharmaceuticals, Inc.
(ISIS)		 Heterozygous Familial Hypercholesterolemia (HeFH) Phase III trial data of Mipomersen January 4, 2010 $11.11
January - February 2010 Synta Pharmaceuticals Corp.
(SNTA)		 Rheumatoid Arthritis (RA) Phase II trial data of Apilimod January 7, 2010 $5.47
February 12, 2010 Cadence Pharmaceuticals, Inc.
(CADX)		 Acute Pain And Fever In Adults And Children FDA approval of Acetavance November 27, 2009 $8.55
February 23, 2010 Salix Pharmaceuticals, Ltd
(SLXP)		 Hepatic Encephalopathy (HE) FDA panel review of Xifaxan January 18, 2010 $26.99
February - March 2010 Ariad Pharmaceuticals, Inc.
(ARIA)		 Metastatic Soft Tissue And Bone Sarcomas Second Interim analysis of the Phase III SUCCEED trial oral Ridaforolimus December 9, 2009 $2.62
SAMPLE TABLE – UPCOMING EVENTS (WITH OPINION) 
 
EVENT DATE
COMPANY
 INDICATION EVENT REPORT DATE REPORT DATE PRICE PEAK SALES/MARKET CAPITAL (%) OPINION
January - February 2010 GTx Inc.
(GTXI)		 Prostate Cancer in Men with High-Grade Prostatic Intraepithelial Neoplasia (PIN) DSMB analysis of the Phase III trial of Acapodene November 26, 2009 $3.87 425.71% Positive
January - February 2010 Vertex Pharmaceuticals Incorporated
(VRTX)		 Hepatitis C Virus (HCV) Infection SVR data from the Phase III (ADVANCE study) trial of Telaprevir November 30, 2009 $39.00 22.63% Positive
January - February 2010 OXiGENE, Inc.
(OXGN)		 Anaplastic Thyroid Cancer (ATC) Phase II/III FACT trial data of Zybrestat December 4, 2009 $1.15 278.47% Negative

 
More Information ©Copyright 2009 New Bio Medicine, LLC. All Right Reserved. Privacy Policy